We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Role of FGF23 and Asymmetric Dimethylarginine (ADMA) in Chronic Kidney Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01317186
Recruitment Status : Unknown
Verified March 2011 by Ankara Education and Research Hospital.
Recruitment status was:  Recruiting
First Posted : March 17, 2011
Last Update Posted : March 17, 2011
Sponsor:
Information provided by:

Study Description
Brief Summary:
In chronic kidney disease calcium (Ca) and phosphate (P) metabolism disorders are very common and also they are one of the leading causes of morbidity in these population. FGF23 is a novel factor that contributes Ca-P disorders. It has been hypothesized that FGF 23 increase is mediated by asymmetric dimethylarginine (ADMA). The aim of the study is to evaluate this hypothesis.

Condition or disease
Metabolic Diseases Chronic Kidney Disease

Study Design

Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Cohort
Study Start Date : March 2011

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts

Group/Cohort
Group I
Stage 2 Non-diabetic Chronic Kidney Disease
Group II
Stage 3 Non-diabetic Chronic Kidney Disease
Group III
Stage 4 Non-diabetic Chronic Kidney Disease


Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Stage 2-4 Non-diabetic Chronic Kidney Disease patients
Criteria

Inclusion Criteria:

  • between ages of 18 - 65 years old
  • chronic kidney disease of stage 2-4

Exclusion Criteria:

  • presence of diabetes mellitus or ischemic hearth disease
  • taking vitamin d therapy
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01317186


Locations
Turkey
Ankara Education and Research Hospital Recruiting
Ankara, Turkey
Contact: Alper AZAK       dralperazak@gmail.com   
Contact: Bülent Huddam       drhuddam@yahoo.com   
Sub-Investigator: Bülent Huddam         
Sponsors and Collaborators
Ankara Education and Research Hospital
More Information

Responsible Party: Bülent Huddam, Ankara Education and Research Hospital
ClinicalTrials.gov Identifier: NCT01317186     History of Changes
Other Study ID Numbers: NEPH002
First Posted: March 17, 2011    Key Record Dates
Last Update Posted: March 17, 2011
Last Verified: March 2011

Keywords provided by Ankara Education and Research Hospital:
FGF 23
ADMA
chronic kidney disease
Ca-P metabolism disorder

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Metabolic Diseases
Urologic Diseases
Renal Insufficiency
N,N-dimethylarginine
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action